In the Phase Ib Beamion LUNG-1 clinical trial, zongertinib, an investigational irreversible tyrosine kinase inhibitor, ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses a recent study he led on the validity of using ...

Early findings from Johnson & Johnson’s Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus ...